Figure 1

Pharmacological treatment with XPO1 inhibitors reduces incidence and increases survival in a model of prostate cancer derived bone metastasis. (A) In vivo schematic representation of the treatments in bone metastatic PCb2 model. (B) Representative X-ray pictures of untreated (vehicle), alendronate or selinexor ( KPT-330) and KPT-251 treated mice collected at 50^th day after intracardiac cell injection and showing strong osteolysis in untreated animals, moderate osteolysis in alendronate and KPT-251 treated animals and no lesions in selinexor treated animals. (C) table summarizing incidence and osteolysis (Lytic units) as measure of tumor burden at 35, 42 and 50 days after tumor inoculation and treatments. (D) serum CTX-I and (E) mTRAP levels measured in control animals and upon treatments. Both panels show the levels of CTX-I and TRAP measured before the death of the animals or in survived animal at the end of follow-up (170 days) (F) Visceral metastases incidence upon treatments in intact nude mice intracardiacally injected with PCb2cells. *P at least <0.05.